Unblocking the CAR-T supply chain
As part of serum replacement, high quality recombinant Human Insulin can improve T Cell expansion and in-vivo function in CAR-T therapy optimization.
Transfer of T Cells genetically modified to target cancer cell antigens (CAR-T therapy) is a promising oncology treatment strategy. The big challenge remains to scale-up the manufacturing process, improve consistency and reduce the costs.
One of the main limiting factors in the manufacturing process is the dependency on human serum, which supports T lymphocyte growth and survival when cultured ex-vivo.
Human serum is expensive, and the current supply chain will not meet the demands when different approved CAR-T therapies become blockbuster treatments. High focus on T-Cell media development has recently allowed several serum-free media to be introduced on the market, with a different proprietary formulation based on key components, such as human insulin.
This is a particularly relevant development for people working in upstream biomanufacturing, R&D, BD and any stakeholder involved in cell line and media development, cell and gene therapy manufacturing focused on bioprocess optimization, high cell viability and high productivity.
The text is created in collaboration with Pharmaceutical Networking.